SAN FRANCISCO – After a number of bumps along the road, confidence has returned and expectations are once again high that the gene therapy and other advanced therapies sector can finally make good on its promise to transform 21st century medicine. That enthusiasm has translated into strong IPO debuts for gene therapy companies and the FDA granting breakthrough status for multiple drug candidates in the space.